Catalent quadruples cold chain capacity at its clinical supply facility in Shanghai, China
The new expansion also includes new dedicated receiving, dispatch and packaging areas.
Catalent Pharma Solutions is to quadruple cold chain capacity at its existing clinical supply storage and distribution facility in Shanghai, China. The expansion is in response to growing customer demand from both domestic and multinational pharmaceutical sponsors and contract research organizations (CROs).
Expansion work at the site is underway and is due to be fully validated and operational by the end of the year. Opened in 2013, the facility was the first in China to provide end-to-end clinical supply solutions from clinical supply management, comparator/reference product sourcing and primary packaging to clinical storage and distribution.
The cGMP site is also validated to support biologics requiring refrigerated and frozen supply chain management and currently offers 15º/25 ºC controlled room temperature, 2º/8 ºC refrigerated, -20 ºC frozen and -80 ºC ultra-low frozen storage environments. The new expansion includes the quadrupling of existing cold chain storage capacity, as well as new dedicated receiving, dispatch and packaging areas.
“In the 2 years since the facility opened, we have seen a sharp increase in the utilization of the site, with a shift towards more trials involving biologics and temperature-sensitive drugs,” commented Wetteny Joseph, Catalent’s President of Clinical Supply Services.
Being located in the Shanghai Free Trade Zone, which is within close proximity of the Pudong and Hongqiao international airports, and other key transport links across China and the broader Asia Pacific region, Catalent’s Shanghai site benefits from expedited customs and clearance processes, as well as the potential elimination of duties, taxes and transportation delays.
Catalent has also added further packaging and low temperature storage capacity to its Singapore facility, citing the need to support secondary packaging and innovative and flexible clinical supply services. “This expansion continues our strategic growth program within the Asia-Pacific region, and follows our announcement in June 2015, that we are increasing capacity at our Singapore clinical supply facility by 60%,” continued Joseph.
With facilities in the US, UK, Germany, Singapore and China, and an extended network of over 50 audited depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, that can help to expedite clinical trials and ensure that customers are reliably supplied where and when needed around the globe.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance